文献速递系统性红斑狼疮血管炎

系统性红斑狼疮中的皮肤血管炎:20年随访的流行病学与危险因素

Cutaneous vasculitis in systemic lupus erythematosus: epidemiology and risk factors over a 20-year follow-up.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于伯明翰狼疮队列392例SLE患者的观察性纵向研究,中位随访9.2年,27%发生皮肤血管炎,其中43.3%有两次及以上事件。皮肤血管炎发生率从入组后前3年的34.4%降至随访18年后的2.1%,与雷诺现象、多系统受累、抗Sm抗体、抗dsDNA抗体及低补体血症相关,而使用硫唑嘌呤和抗疟药呈反向关联。

要点

  • 27%的SLE患者发生皮肤血管炎,其中43.3%经历两次及以上事件。
  • 皮肤血管炎发生率从入组后前3年的34.4%降至随访18年后的2.1%。
  • 硫唑嘌呤和抗疟药的使用与皮肤血管炎发生呈反向关联。

核心结论

  • SLE患者皮肤血管炎发生率随随访时间下降,且与明确的临床、血清学及治疗相关因素相关。

研究设计与样本

  • 伯明翰狼疮队列为SLE患者的观察性纵向队列,患者在满足第4条ACR标准后3年内入组。
  • 共纳入392例患者,95.7%为女性,中位随访9.2年(四分位距5.1-14.7年)。
  • 采用多变量共享脆弱性Cox比例风险模型识别与皮肤血管炎发生相关的临床、实验室及治疗变量。

主要发现

  • 皮肤血管炎发生于27%的SLE患者,其中43.3%有两次及以上皮肤血管炎事件。
  • 皮肤血管炎发生率从入组后前3年的34.4%(95%CI 29.7,39.3)降至随访18年后的2.1%(95%CI 0.05,11.5)。
  • 皮肤血管炎发生与雷诺现象、全身症状、黏膜皮肤、肌肉骨骼、血液学及心血管受累、抗Sm抗体、抗dsDNA抗体及低补体血症相关。
  • 硫唑嘌呤和抗疟药的使用与皮肤血管炎发生呈反向关联。
  • 发生皮肤血管炎的患者更可能发生至少一项器官损伤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cutaneous vasculitis (CV) is common in SLE, but the epidemiology and risk factors remain unclear. We aimed to identify the trends and risk factors for CV in patients with SLE over a period of 20 years. METHODS: The Birmingham Lupus Cohort is an observational longitudinal cohort of SLE patients. Patients were enrolled within 3 years of meeting their fourth ACR criterion. Disease activity, laboratory test results and treatment records were collected. A multivariable shared frailty Cox proportional hazard model was used to identify clinical, laboratory and treatment-related variables associated with the development of CV. RESULTS: We included 392 patients: 95.7% were female. The median (interquartile range) duration of follow-up was 9.2 (5.1-14.7) years. CV occurred in 27% of SLE patients, of whom 43.3% had two or more CV events. This study demonstrated a marked decline in the incidence rates of CV, decreasing from 34.4% (95% CI 29.7, 39.3) during the first 3 years after enrolment to 2.1% (95% CI 0.05, 11.5) after 18 years of follow-up. Development of CV was associated with RP, constitutional, mucocutaneous, musculoskeletal, haematological and cardiovascular involvement, anti-Sm antibodies, anti-dsDNA, and hypocomplementemia. However, the use of AZA and antimalarials was inversely associated with the development of CV. Patients with CV were more likely to develop at least one item of organ damage. CONCLUSIONS: The incidence rates of CV in SLE decreased over the follow-up period and CV is associated with defined clinical, serological and treatment-related factors.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Saleh A, Yee CS, Acquah A, et al. Cutaneous vasculitis in systemic lupus erythematosus: epidemiology and risk factors over a 20-year follow-up. Rheumatology (Oxford). 2025. PMID: 39661484. doi:10.1093/rheumatology/keae672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。